ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
ZEVRA THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIPLYFFA | $30.20M | $24.60M | $26.40M | $22.40M | $21.50M | $17.10M | – | – | – | – | – | – | 76.1% | +40.5% |
| OLPRUVA | $200.00K | $300.00K | – | $100.00K | $300.00K | $100.00K | – | $0 | $0 | – | – | – | 0.5% | -33.3% |
| Consulting Services [Member] | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
| OLPRUVA | – | – | – | – | – | $100.00K | – | – | – | $100.00K | – | – | – | – |
| License | – | – | – | $0 | $0 | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Zevra Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.